• All
  • Company News
  • Culture
  • Mission
  • Press Releases
  • Research and Technology
  • Top Stories

Meet Our Interns!

We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.


COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022

COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.


COTA Descends on NYC for CAMP COTA

After two years, COTA was back together in NYC for an in-person all-hands meeting. As much as we have learned to adapt to the world of remote work, there is no substitute for the connection, collaboration, and energy that comes from physically being in the same space.


Miami Cancer Institute Takes Action To Address Inequities in Cancer Care with Expanded COTA, Inc. Collaboration

Miami Cancer Institute, part of Baptist Health South Florida, will leverage COTA’s Real-World Analytics to drive standardization of care across all cancer patients


Creating a Clear Path to Precision Oncology with Real-World Data

ViVE 2022 brought together thought leaders addressing key disparities and the future of healthcare. Our own C.K. Wang, alongside expert oncologists and technology innovators stressed the need for understanding what “precision oncology” really is.


Leading COTA into the Next Chapter of Data-Driven Precision Oncology

I’m delighted to be leading COTA at this pivotal moment in history, when precision oncology and data science are advancing together at lightning speed. By working with partners across the healthcare continuum, we can guide cancer patients and their families down the path to clear, safe, personalized, and effective cancer care.


Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.


To Help Accelerate Development of Cancer Treatments with Real-World Data, COTA Welcomes Kevin Schweikert as Vice President, Life Sciences

COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.


From Regulatory to RWD: A Journey to Improve Cancer Care with COTA

Working with the FDA and now COTA Laura describes why real-world data is an integral part of today’s patient care.


Interested in receiving updates on our latest posts?

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.